Summary.-The effect of chemotherapy on natural killer (NK) activity and antibodydependent cell-mediated cytotoxicity (ADCC) in 15 advanced carcinomas of the lung was examined with regard to the drug, dose, route and timing of administration. The relationship between the effect of chemotherapy on the prognosis for the patients, and the changes in NK activity and ADCC, was also analysed. The NK activity and ADCC in patients with poor prognosis were significantly subnormal, even before treatment. The NK activity and ADCC began to decrease 2 weeks after the initiation of treatment and reached the lowest level during the 3rd or 4th week in all patients. Thereafter, they returned to the pretreatment level in 8 patients with stabilized disease. In contrast, they were not restored in 7 patients with progressive disease and poor prognosis. In 4 patients it was found that the effect of chemotherapy with pepleomycin and carbazilquinone on NK activity and ADCC differed according to the drug used. From this pilot study it is suggested that NK activity and ADCC are valuable prognostic factors in patients with advanced carcinoma of the lung, and that detailed analysis of the effect of each anticancer agent on NK activity and ADCC is desirable for the establishment of better treatment regimens for advanced carcinoma of the lung.
IN ADDITION to killer T cells and macrophages, natural killer (NK) cells
and killer (K) cells are thought to play an active role in the in vivo resistance to tumour development and growth (Herberman & Holden, 1979; Habu et al., 1981) . There are two purposes in the clinical measurement of NK activity and antibody-dependent cell-mediated cytotoxicity (ADCC) which is mediated by K cells. One of them is to establish a relevant and reproducible method by which host modification through treatment can be assessed (Hersh, 1 981) . The other is to develop a reliable monitoring procedure for determining an effective treatment protocol. The conventional nonspecific imnmune responses such as skin reaction to PPD, blastogenic response to phytohaemagglutinins, T-and B-cell subpopulations, and T-cell subsets (Ty and T,u cells) can be easily determined (Sone et al., 1977) , but the relationship between the effect of treatment or the prognosis of tumour-bearing patients and the changes in these parameters has been relatively obscure. It is of interest, therefore, to ascertain whether there is any correlation of NK activity and ADCC with the clinical course of cancer, and it is necessary to know the NK activity and ADCC in tumour-bearing patients before the investigation of specific cytotoxicity for tumourassociated antigens can proceed.
Correspondcel to Nagalhiro Saijo, A 1).
According to our previous data, NK activity is not decreased before chemotherapy in patients with Stage IIIMo or IIIM1 carcinoma of the lung or with metastatic pulmonary tumours. It is decreased only in patients with poor performance status, and is significantly decreased after chemotherapy. ADCC also shows a tendency to decrease in tumourbearing patients after chemotherapy (Saijo et al., 1981 (Saijo et al., , 1982a . In this study, 15 previously untreated patients with carcinoma of the lung treated by chemotherapy alone were examined for NK activity and ADCC before treatment and weekly for 6 weeks after treatment. The effect of anticancer agents on NK activity and ADCC was examined with regard to the drug, course, route and timing of administration. The relationship between the effect of treatment and prognosis for the patients with the changes in NK activity and ADCC was also analysed. Table 1 . There were 4 squamous-cell carcinomas, 7 adenocarcinomas, 1 large-cell carcinoma and 3 small-cell carcinomas.
Treatment.-All the patients were randomly assigned to the chemotherapeutic regimens listed in Table II . These regimens for carcinoma of the lung were established according to a modification of the uniform cancer chemotherapy protocol used in national hospitals in Japan. As shown in Table II , all regimens were completed within 4 weeks of the beginning of treatment. In 3 patients with pleural effusion, an attempt was made to drain as much of the effusion as possible by tube drainage, and an anticancer agent, mitomycin C (10 mg) or adriamycin (40 mg), in 20-40 ml of normal saline was administered i.p. once or twice weekly.
One patient (F.S.) was given Nocardia rubra cell-wall skeleton (N-CWS, 500 jug) once i.p. Except for one patient (Y.K.) who Follow-up every week included checking the clinical status of the patient, and recording symptoms, side effects of the drugs, ECOG performance status (PS), and tumour measurement in the chest roentgenogram. Immunological tests for NK activity and ADCC were also made every week.
At 6 weeks, the therapeutic response of the primary tumour and metastatic lesions (including pleural effusion) was evaluated. The therapeutic responses were defined as follows: complete response (CR), disappearance of all symptoms and signs of disease for at least 4 weeks; partial response (PR), a decrease of ) 50% in the product of the 2 largest perpendicular diameters in all measurable lesions, with no lesions developing for at least 4 weeks, or unequivocal regression of evaluable but unmeasurable lesions; stable disease (SD), < 50% decrease and <25% increase in the product of the 2 largest perpendicular diameters of all measureable lesions for at least 4 weeks; progressive disease (PD) > 25% increase in the size of any lesion, or appearance of new lesions.
Preparation of lymphocytes.-Peripheral blood was obtained by venepuncture with a needle attached to a plastic syringe containing heparin. The blood was diluted 1:1 with Eagle's minimum essential medium (MEM), and the mononuclear cells were separated by centrifugation on a Ficoll-Conray cushion (1080 g) according to Boyum's method (Boyum, 1968 Anti-PC-9 antibody.-The antibody used for the ADCC assay was raised in an NZW rabbit immunized by i.v. injection of PC-9 cells (3 x 107/3 ml) once a week for 5 weeks. The pre-immune rabbit serum was used as a control in the ADCC assay. The immune and pre-immune sera were decomplemented by heating at 56°C for 30 min, and absorbed extensively with human type-AB RBC. The absorbed sera were decomplemented again before the experiments.
The appropriate dilution of immune serum was between 1 :100 and 1:1000 (Fig. 1) . Therefore, immune serum diluted 1: 256 was used for ADCC assay in all experiments. The values for ADCC with the pre-immune serum were almost the same as those for NK activity (Fig. 1) .
Labelling of tumour cells. Cytotoxicity assay. For the determination of NK activity, 0 lml quantities of the targetcell suspension (105/ml) wNere mixed with serial 2-fold dilutions of 0 1 ml of the lymphocyte suspension (1 25-10 x 106/ml) wAhich produced a final effector: target ratio of 12 5-100: 1. The reaction mixture w%Nere carried out in the wells of 96-well V-bottomed inicrotitre plates (Limbro Scientific Co.. Hamden, Conn, U.S.A.). These plates were incubated in a humidified atmosphere of 500 CO2, 95%o air at 37°C for 6 h.
For the determination of ADCC, 51Cr-labelled PC-9 cells (104 in 0 05 ml of RPMI-FCS) and 0 05 ml of anti-PC-9 antibody (diluted 1:256 in RPMI-FCS) were incubated in microtitre plates in a humidified atmosphere of 500 C02, 950o air at 37°C for 1 h. Effector cells in 0 1 ml (I 25-10 x 106/ml) were added and incubation was continued for 6 h.
After incubation all the plates were centrifuged at 400 g for 10 min, and 0P1 ml of the supernatant from each well was removed and its radioactivity was counted by an auto-y-counter. Spontaneous target-cell release was determined from the supernatant of target cells cultured without effector cells. 
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Weeks after the beginning of treatment 
Weeks after the beginning of treatment these activities tended to be restored 5 weeks after the initiation of treatment. In Patient M.S. they returned to pretreatment levels in 6 weeks. On the other hand, these activities decreased again 1 week after the bronchial-artery infusion of 8 mg CQ in Patient Y.K. These results suggest that small divided doses of PLM did not reduce NK activity and ADCC, and that the two administrations of 6 mg CQ weekly induced the marked decrease in these activities; in addition, administration of CQ by the intra-arterial route had the same effect as by the i.v. route. 
Weeks after the beginning of treatment Weeks after the beginning of treatment As shown in Fig. 6 , NK activity and ADCC decreased 1 week after the initiation of treatment, stayed low through the 2nd week, and showed slight recovery by the 3rd week in patient CN. In Patient S.S., 20 mg of i.v. PLM alone had no effect upon NK activity or ADCC. After the beginning of simultaneous administration of PLM and CQ, the activities decreased, and did not return to pretreatment levels. Fig. 7 shows the changes in NK activity and ADCC in patients receiving large intermittent doses of PLM alternately with CQ. The responses to treatment were SD in H.A., and PD in T.K. The changes in NK activity and ADCC were essentially the same as in Fig. 6 . Again PLM alone did not affect either activities, and the administration of CQ apparently decreased both.
DIISCUSSION
In clinical practice, a number of tests are conducted to determine the immune reactivity of the patient (Hersh, 1981; Sone et al., 1977) . The principal cell in immunological surveillance against cancer has been thought to be the T cell. However, multiple immunological methods to evaluate the T-cell functions have failed to confirm a major role for the T cell in immunological surveillance, since it is difficult to demonstrate a good correlation between the reactivity of the T cell and the prognosis of the cancer. The role of other potential antitumour effector cells such as NK cells, K cells and macrophages needs more intensive investigation (McCredie et al., 1979; Saijo et al., 1980, The in vivo significance of NK activity and ADCC is still unclear, but these activities seems consistent with the existence of a surveillance mechanism against tumour growth (Menon & Stefani, 1978) . The potential role of NK activity and ADCC in human cancer is now under extensive investigation, in spite of the inconsistent levels of NK activity and ADCC in tumour-bearing patients (Eremin et al., 1978; Forbes et al., 1981a, b (Saijo et al., 1982b) . However, the kinetics of the action of anticancer agents against NK activity and ADCC are complicated. MIantovani et al. (1978) reported that azathiopurine and cyclophosphamide induced an apparent decrease in NK activity of mouse spleen lymphocytes 2 days after administration of the drug. On the other hand, Santoni et al. (1980) demonstrated an elevated NK activity in peritoneal lymphocytes and a decrease in spleen lymphocytes after the administration of Adriamycin. There are not enough data about the effect of anticancer agents on ADCC. McCredie et al. (1979) reported that in patients with normal K-cell activity surgery had no effect oni ADCC, but in those with low values before surgery there was a maximal decrease at 5 days, with recovery by 15 days, and that radiotherapy caused a marked decrease in ADCC, maximal at 4 weeks, with recovery by about 12 weeks in those who had no known local or distant disease after the completion of treatment.
In this study, it was demonstrated that NK activity and ADCC in 7 patients with poor prognosis were significantly decreased even before treatment, and that they began to decrease 2 weeks after the initiation of treatment and reached the lowest level at 3-4 weeks in all patients. Thereafter, the activities returned to the pretreatment level in 8 patients with stabilized disease; in contrast, they were not restored in 7 patients with progressive disease and poor prognosis. These results suggest that NK activity and ADCC are valuable prognostic factors in patients with Stage IIIMo and IIIM1 carcinoma of the lung. In addition, we clearly demonstrated that the effect of chemotherapy on NK activity and ADCC differed according to the drug used. Administration of CQ apparently decreased in NK activity and ADCC, irrespective of the route of administration. On the other hand, the effect of PLM was not clearly detected irrespective of timing, dose or route of administration. It should be stressed that the detailed analysis of the effect of each anticancer agent on NK activity and ADCC is necessary for the establishment of better treatment regimens for advanced carcinoma of the lung (Saal et al., 1977) . In spite of the promising results of an attempt to monitor the immune system in patients with Stage IIIMo and IIIM1 carcinoma of the lung, the phenomena observed in this pilot study still await statistical confirmation in a larger, controlled, more systematic study. The complexities inherent in the clinical situation and chemotherapeutic regimens make it premature to engage in detailed speculation about the precise role played by the circulating cytolytic lymphocytes. In addition, plastic nonadherent cells were used as effector cells of NK and ADCC assay throughout this study. The composition of the lymphocyte population in the blood is an essential factor for further assessment of the significance of these data. Nevertheless, we are encouraged by having a test available which may give reproducible information on chemotherapy induced effects on immune reactivity and which may correspond to the course of the neoplastic disease.
